share_log

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $16 Price Target

HC Wainwright & Co.重申买入Esperion Therapeutics,维持16美元的目标股价
Benzinga ·  05/08 09:33

HC Wainwright & Co. analyst Joseph Pantginis reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $16 price target.

HC Wainwright & Co. 分析师约瑟夫·潘吉尼斯重申Esperion Therapeutics(纳斯达克股票代码:ESPR)的买入并维持16美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发